

## **Mohamad Mohty**

Mohamad Mohty is Professor of Hematology and head of the Hematology and cellular therapy Department at the Saint-Antoine Hospital and University Pierre & Marie Curie (Paris, France). Professor Mohty obtained his medical degree from the University of Montpellier, France, and his PhD from the University of Marseille, France. Before moving to Paris, he was head of the Transplant Program at the University-Hospital of Nantes, France. He also undertook post-doctoral work at the Hematology Department, Imperial College, Hammersmith Hospital, London, UK. Professor Mohty's translational research activity is focused on the pathophysiology of graft-vs-host disease and the immunobiology of normal and pathological antigen-presenting cells, especially the **impact of novel immunomodulatory agents such as IMiDs and hypomethylating agents**. He has a special clinical focus on the development of reduced-toxicity conditioning regimens, immunotherapy and **different aspects of therapy of multiple myeloma**.

Professor Mohty is chairman of the Acute Leukemia Working Party (ALWP) **and president-elect of the European Group for Blood and Marrow Transplantation (EBMT)**. He serves on the board of the EBMT, and the "Intergroupe Francophone du Myelome" (IFM). He is a member of the American Society of Hematology, American Society for Clinical Oncology, American Society for Blood and Marrow Transplantation, European Hematology Association, International Society for Experimental Hematology, and EBMT.

Professor Mohty has published more than 210 peer-reviewed articles in the field of stem cell transplantation, leukemia and myeloma, in different hematology and immunology journals. He also serves as an Associate Editor for *Leukemia*, *Bone Marrow Transplantation*, *European Journal of Haematology* and *Blood Cancer Journal*, as a member of the editorial board of *Haematologica*, and as a regular reviewer in different immunology, hematology, and cancer journals such as *Blood* and *The Lancet*.